In recent years, silymarin has gained significant attention for its potential use in cancer treatment due to its ability to inhibit the growth of cancer cells and reduce the side effects of chemotherapy. Silymarin has been shown to have a protective effect against several types of cancer, including breast, prostate, lung, liver, and skin cancer. Research is ongoing to explore the full potential of silymarin in cancer treatment and its mechanisms of action.
Table of Contents
What is Silymarin?
The flavonoid silymarin extracted from the seeds of Sylibum marianum is a mixture of 6 flavolignan isomers out of which the 3 most important are silybin (or silibinin), silydianin, and silychristin. The standardized extract obtained from the dried seeds of Silybum marianum (milk thistle) contains approximately 70% to 80% of the silymarin complex and an approximately 20% to 30% chemically undefined fraction, comprising mostly other polyphenolic compounds. The main component is silybin (silibinin).
This group of flavonoids has been extensively studied and they have been used as hepato-protective substances in nonalcoholic fatty liver disease with favorable results; in the reduction or inhibition of hepatic fibrosis: silymarin showed the ability to reduce hepatic fibrosis in the early stages of liver injuries; and also in cirrhosis: silymarin decreased mortality in patients with hepatic cirrhosis.
The history of silymarin uses
There is a long history of silymarin use in human diseases without toxicity after prolonged administration:
Silymarin has been used in Europe since the fourth century BCE to treat serpent venom bites. It was also used in Ancient Egypt. Later on, during the Renaissance, some of the therapeutic effects were discovered and published. In the seventeenth century, an English botanist, Nicholas Culpeper, suggested that milk thistle was useful for liver diseases.
Recently, Silymarin has been proposed for the treatment of many different diseases such as Alzheimer’s dementia; SARS-2 Covid-19; diabetes and its complications; hyperlipidemia and hypercholesterolemia, etc. However, in the last 15 years, the main focus has been cancer prevention and treatment.
Silymarin in Cancer Treatment
Silymarin compounds have clear anticancer effects. Some of them are:
- decreasing migration through multiple targeting,
- decreasing hypoxia,
- inducing apoptosis in some malignant cells, and inhibiting promitotic signaling among others.
It is a unique virtue that the antitumoral activity of silymarin compounds is limited to malignant cells while the nonmalignant cells seem not to be affected.
Here are a few examples of recent findings on silymarin anticancer activity for different types of cancer:
- Melanoma: Silymarin decreased the growth of and inhibited tumor growth in vitro and in vivo and has been proposed for chemoprevention of melanoma.
- Prostate: Silibinin treatment caused growth inhibition, apoptosis, and decreased viability in different prostate cancer cell lines.
- Lung: Silibinin showed enhanced antitumor activity.
- Bladder: Silibinin reversed chemotherapeutic resistance in bladder cancer cells and decreased bladder cancer metastasis and prolonged animal survival.
- Pancreas: Silibinin-induced cell cycle arrest and apoptosis in certain pancreatic cancer cell lines.
- Breast: Silibinin synergized with conventional chemotherapeutic drugs in anticancer effects on breast cancer cells.
- Colon: Silibinin inhibited proliferation and increased apoptosis in colon cancer cells.
- Liver: Silibinin decreased cell proliferation and migration of human hepatocellular cancer cells.
- Ovary: Silibinin decreases tumor growth in vitro and in vivo.
- Hematologic: Silibinin-induced differentiation of acute myeloid leukemia cells and Epstein-Barr positive lymphoma cell proliferation was inhibited.
Reseaches about Silymarin's anti-cancer effects
Although many research results confirm the anti-cancer activity of silymarin, four interesting clinical case reports are also available and suggest a need for further studies.A Taiwanese patient (66 years old) with a regression of an 11 cm diameter hepatocellular carcinoma received 450 mg of silymarin daily, and no other medication. The complete regression of an advanced unresectable hepatocellular carcinoma treated with sorafenib and silymarin. 2 cases of brain metastases from lung cancer in which the treatment with silymarin decreased edema and the size of metastases, without improvement of the primary tumor.
Silymarin’s strong antioxidant activity makes it a useful drug in cancer prevention.
Its characteristics also define an anticancer drug: it has the ability to interfere with the expression of proteins related to cell cycle regulation, apoptosis, angiogenesis, and multidrug resistance.
Research suggests that silymarin should be used at high doses in cancer treatment.
Silymarin’s lack of toxicity, even at very high doses, and the lack of effects on normal cells are important reasons for its further development.
Read about another benefit of Silymarin: Detoxification with milk thistle >